<\/p>\n\n\n\n
<\/p>\n\n\n\n
Giant pituitary tumors (>40 mm) present a major therapeutic challenge due to the lack of established guidelines. This retrospective study analyzes a large cohort of patients managed by an expert multidisciplinary team, focusing on treatments and postoperative outcomes.<\/p>\n\n\n\n
\u2022 Retrospective study on giant pituitary tumors (>40 mm).<\/p>\n\n\n\n
\u2022 Exclusion of macroprolactinomas responsive to dopamine agonists.<\/p>\n\n\n\n
\u2022 Surgery performed by a single team, mainly via endoscopic endonasal approach.<\/p>\n\n\n\n
\u2022 Follow-up included hormone replacement therapy, radiotherapy, and anti-tumor medical treatments.<\/p>\n\n\n\n
<\/p>\n\n\n\n
\u2022 63 patients<\/strong> included, most presenting with visual impairments.<\/p>\n\n\n\n \u2022 Surgical interventions<\/strong>: 59% operated once, 40% twice, 1% three times.<\/p>\n\n\n\n \u2022 Tumor types<\/strong>: Gonadotroph (67%), corticotroph (14%), somatotroph (11%), lactotroph (6%), mixed GH-PRL (2%).<\/p>\n\n\n\n \u2022 Visual improvement<\/strong> in 89% of patients with preoperative visual deficits.<\/p>\n\n\n\n \u2022 Severe surgical complications<\/strong> in 11% of cases, mostly for tumors >50 mm requiring a transcranial microscopic approach.<\/p>\n\n\n\n \u2022 Additional treatments<\/strong>:<\/p>\n\n\n\n \u2022 Radiotherapy required for 29% of patients (3 to 56 months after surgery).<\/p>\n\n\n\n \u2022 Temozolomide treatment needed for 6% of patients (19 to 66 months after surgery). Giant pituitary tumors require a multimodal management approach where surgery plays a central role. Expert multidisciplinary care allows for better tumor control and significant clinical improvement.<\/p>\n\n\n\n <\/p>\n\n\n\n
<\/p>\n\n\n\nConclusion<\/h3>\n\n\n\n